Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about IMTX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Nab-paclitaxel | Melanoma, Cutaneous Malignant | Phase 3 · NCT06743126 | Recruiting |
| Anzutresgene Autoleucel (IMA203) | Melanoma, Cutaneous Malignant | Phase 3 · NCT06743126 | Recruiting |
| Renal Cell Carcinoma Peptides Vaccine IMA901 | Metastatic Renal Cell Carcinoma | Phase 3 · NCT01265901 | Completed |
| Sunitinib | Metastatic Renal Cell Carcinoma | Phase 3 · NCT01265901 | Completed |
| Therapeutic Liver Cancer Peptide Vaccine IMA970A | Hepatocellular Carcinoma | Phase 1/2 · NCT03203005 | Completed |
| Monoclonal Antibody | Refractory Cancer | Phase 1/2 · NCT05958121 | Recruiting |
| IMA402 and IMA401 | Refractory Cancer | Phase 1/2 · NCT05958121 | Recruiting |
| Cytotoxic Chemotherapeutic Agent | Refractory Cancer | Phase 1/2 · NCT05958121 | Recruiting |
| IMA402 and checkpoint inhibitor | Refractory Cancer | Phase 1/2 · NCT05958121 | Recruiting |
| IMA402 | Refractory Cancer | Phase 1/2 · NCT05958121 | Recruiting |
| IMA203CD8 Product | Refractory Cancer | Phase 1/2 · NCT03686124 | Recruiting |
| IMA 950 | CNS Tumor, Adult | Phase 1/2 · NCT01920191 | Completed |
| Arm B: Paclitaxel | Merkel Cell Carcinoma | Phase 2 · NCT02054884 | Terminated |
| Colorectal Tumor-Associated Peptides Vaccine… | Colorectal Carcinoma | Phase 1/2 · NCT00785122 | Completed |
| Synthetic Glioblastoma Tumor-associated… | Glioblastoma | Phase 1 · NCT02149225 | Completed |
| IMA401 (Phase Ia) | Refractory Cancer | Phase 1 · NCT05359445 | Active not recruiting |
Also used in these trials (approved or third-party drugs, not IMTX's own candidates): Temozolomide, Recombinant Granulocyte-Macrophage Colony-Stimulating Factor, Ipilimumab, Lifileucel, Nivolumab, Relatlimab, Paclitaxel, Dacarbazine, Cyclophosphamide, Pembrolizumab, Poly ICLC, Sargramostim.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
IMTX holds $276.6M in cash and short-term investments and burns about $55.5M/quarter from operations, an estimated runway of 15 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 40 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IMTX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc | Institution (13G, 5%+) | 25,149,155 | 18.76% | 2026-09-30 |
| Vestal Point Capital, LP | Institution (13G, 5%+) | 15,515,304 | 11.57% | 2026-09-30 |
| RTW Investments, LP | Institution (13G, 5%+) | 12,869,340 | 9.60% | 2026-03-31 |
| PERCEPTIVE ADVISORS LLC Director · +48,000 options |
Insider | 11,246,516 | 8.39% | 2026-08-26 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | Institution (13G, 5%+) | 11,190,129 | 8.35% | 2025-12-31 |
| Montanova Capital, LLC | Institution (13G, 5%+) | 8,750,816 | 6.53% | 2026-09-30 |
| The Toronto-Dominion Bank | Institution (13G, 5%+) | 7,436,342 | 5.55% | 2026-03-31 |
| Mathias Hothum Director · +48,000 options |
Insider | 329,521 | 0.25% | 2026-03-17 |
| Jasuja Harpreet Singh Chief Executive Officer, Director |
Insider | 217,241 | 0.16% | 2026-03-18 |
| Peter Alan Chambre Director · +48,000 options |
Insider | 105,987 | 0.08% | 2026-03-18 |
| Carsten Alexander Johannes Reinhardt Chief Development Officer |
Insider | 47,781 | 0.04% | 2026-03-18 |
| Steffen Martin Walter Chief Operating Officer |
Insider | 10,000 | 0.01% | 2026-03-18 |
Share count 134,071,432 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IMTX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →